Abbott and Medtronic DES double hit likely to increase impact on competitors
This article was originally published in Clinica
Abbott's Xience and Medtronic's Endeavor are highly likely to reach the US market at the same time - during the first quarter of 2008 - causing a bigger than expected impact on competing firms, say analysts. The double approval will mean that rivals Boston Scientific and J&J will not have time "to establish a foothold against newer entrants", said Morgan Stanley analyst Glenn Reicin. The prediction comes after Mr Reicin reported that the FDA has approved the manufacturing facility where Xience is to be produced. If the Xience DES is approved by the end of the first quarter, it could add $150m to Abbott's 2008 sales, said the analyst.
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.